Analog Design for Hypodermic Drug Delivery by Parmanand, Archit Santosh & Harris, Norman Henry
Worcester Polytechnic Institute
Digital WPI
Major Qualifying Projects (All Years) Major Qualifying Projects
April 2015
Analog Design for Hypodermic Drug Delivery
Archit Santosh Parmanand
Worcester Polytechnic Institute
Norman Henry Harris
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/mqp-all
This Unrestricted is brought to you for free and open access by the Major Qualifying Projects at Digital WPI. It has been accepted for inclusion in
Major Qualifying Projects (All Years) by an authorized administrator of Digital WPI. For more information, please contact digitalwpi@wpi.edu.
Repository Citation
Parmanand, A. S., & Harris, N. H. (2015). Analog Design for Hypodermic Drug Delivery. Retrieved from
https://digitalcommons.wpi.edu/mqp-all/937
1 | P a g e  
 
Analog Design for Hypodermic Drug 
Delivery 
 
 
A Major Qualifying Project (MQP) 
Submitted to the Faculty of 
WORCESTER POLYTECHNIC INSTITUTE 
In partial fufillment of the requirements for the 
Degree of Bachelor of Science 
 
 
Archit Parmanand (BE)     Norman Harris (BE) 
 
ADVISORS: 
 
 
Aparajit Naram, M.D.        Anjana Jain, Ph.D. 
(UMass Medical School)       (Worcester Polytechnic Institute) 
 
 
This report represents work of WPI undergraduate students submitted to the faculty as 
evidence of degree requirements. WPI routinely publishes these reports on its website without 
editorial or peer review. For more information about the project program at WPI, see 
http://www.wpi.edu/Academics/Project 
2 | P a g e  
 
1 Abstract 
In 2014, 8.9 million procedures were performed in plastic and reconstructive surgery, 
which has increased 10 fold since 1997. Within this field there is an increasing need for accurate 
and ergonomic delivery of hypodermic injections such as Botox™ and dermal fillers. To 
accomplish this task, the design team designed a completely analog delivery device that aids 
surgeons in accurate and efficient placement of hypodermic injections reproducibly and 
repeatedly, without fatigue for the surgeon.  
The design is in two parts: a design for the ergonomic shell, and a design for the volume 
deposition mechanism. The ergonomic shell was designed to fit vertically within the hand and 
rest comfortably on the index finger and first web space. The volume deposition mechanism was 
designed to allow push button administration of a single aliquot of drug while preventing 
inaccuracy in volume and flow rate. Significant roadblocks prevented the creation of a final 
prototype device. However, based on the design process and outcomes, a set of future updates 
has been laid out to improve the design and integrate the deposition mechanism and shell. 
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1 Introduction 
Over the past 60 years, Botulinum toxin has been developed into an effective drug for use 
in cosmetic and reconstructive surgery. Botulinum toxin type A is commonly distributed as 
Botox, and is administered in widely varying circumstances, from facial wrinkles to Upper 
Motor Neuron Syndrome. The minute quantities used and the relatively high cost of production 
make the final Botox™ solution extremely expensive for the physicians and patients (Nigam, 
2010). 
Effective delivery of Botox™ and other, various, dermal fillers, are based solely on the 
physician’s ability to inject the solution into the proper layers of the skin. While controlling the 
flow rate, applied amount, steadiness of syringe and needle, and numerous other patient 
interactions. User fatigue can also lead to medical conditions for the user, increasing the potential 
risks for the patient. This multifaceted delivery approach requires management of many variables 
and does not allow for accurately repeated results. 
1.1 Current Standards for Delivery 
Through the expertise of Dr. Aparajit Naram, at the University of Massachusetts Medical 
Center, the design team have been tasked with designing a device that will help alleviate these 
concerning extra variables, while allowing the physician to accurately deliver multi aliquot drug 
therapies to a patient.  
The current standard has been used for decades to deliver small quantities of drug 
subcutaneously. This method involves use of a hypodermic needle and small syringe. The 
syringe is locked into the hypodermic needle via a pressure fit or “Luer Lok”, and the drug is 
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loaded into the syringe via mechanical actuation of the syringe plunger. The drug is then ready to 
be deposited by the physician.  
Deposition is again a fully manual process. By placing the index and middle finger on the 
wings of the syringe and actuating the plunger, the physician can control the serum’s injection 
into the patient. He must do this while monitoring patient movement, depth of the needle, 
quantity and flow rate of dose, among other patient variables. 
The device allows the user to insert a specific sized syringe into the device. The syringe 
is loaded into the device; a press of a lever or button activates the device to drive the syringes 
plunger a distance specific to the volume. When the device is pressed the plunger will fully 
descend, the mechanism will then fully recoil to its full extend allowing the device to be used to 
deliver the preset volume again. When the user is done, the syringe and needle can be safely and 
easily removed from the device and thrown away. The device itself never comes in direct contact 
with the patient or liquid involved in the procedure.  
1.2 Project Scope 
The fully analog solution has the ability to aid physicians across the globe. Cosmetic 
surgery is a 1.3 billion USD industry, with over 6 million patients receiving Botox™ treatments 
annually (American Society of Plastic Surgeon - ASPS, 2014). By reducing wastage and 
increasing the affectivity of delivery of Botox, the project will be aiding these patients and 
physicians both financially and medically.  
Cosmetic Botox™ treatments can cost anywhere from 400 to 600 USD per treatment and 
as such every drop counts (Naram, 2014). By reducing wastage and run off, physicians and 
patients can see significant monetary gains over the course of their treatment. Per aliquot savings 
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can be estimated to be roughly 3-4 dollars (Naram, 2014). Over the course of one procedure the 
patient can receive anywhere from 10 to 20 aliquots. This brings savings of up to 80 USD per 
treatment or 13%-18% of the total cost of the procedure. 
The device is also economically cost-effective because of its lack of electrical and digital 
components. With the lack of electrical components, the cost of manufacturing will be reduced, 
in comparison to the current devices on the market. This will benefit the user by reducing the 
upfront cost of purchasing the device and mitigating the long-term cost of replacing disposable 
parts.  
The opportunity for designing and marketing this device stems from the lack of a clinical 
grade alternative to the current method of syringe and needle, leaving the current manual 
injection technique as the only option. The current method allows for significant error and, as 
mentioned above, leaves many variables unchecked.  
1.3 Project Goals and Approach 
The overall goal of the project is to create an ergonomic, analog drug delivery device that 
will allow for user, depth dependent application of multi aliquot drugs to a patient, safely and 
precisely. 
These goals were achievable and were tracked via the design process. Using the general 
design process for development of the device, we were better equipped to handle the needs of the 
project and meet the goals of the advisor and sponsor Dr. Naram. In general we used checkpoint 
meetings to aid in communication with the advisors and display deliverables. These deliverables 
will are tracked by a Gantt charts that we populate using an agreed upon set of deliverables.  
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We used iterative design strategies using a base design to explore ergonomics, plunger 
actuation and other design facets. The main deliverables are: 
 Initial ergonomic design 
 Initial deposition mechanical design 
 Combined ergonomic and mechanism design 
 Finalized ergonomic and mechanism design for use with testing and further fine-tuning. 
The goal for the project is to produce a final design for an ergonomic shell and 
mechanical deposition system that would be used for future manufacturing and production.  
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2 Background 
Through examination of technical sources and other laboratory analogues, we look to 
support the design and technical considerations. This product, industry, and technical 
background built a basis of knowledge for the project and provided greater insight into the needs 
and objectives that the sponsors and team share. This section will discusses the scope and need 
for the project, and moves towards a description of the industry. Also included is a summary of 
the uses of Botulinum Toxin A, current methods of delivery and lab-grade analogues. Further 
description is given for the manufacturing of the device via 3D printing and potential 
mechanisms used throughout the iterative design process. 
2.1 Project Scope and Need 
 As the industry grows and use of Botox™ and other hypodermic injections 
increases over time, there is continued room for improvement of methods to increase affectivity 
of treatments and methods of delivery. Within the scope of Botox™ delivery, the affectivity of 
treatment is very much based on the physician's skill and ability to reproduce the same action 
repeatedly for different spots around the face.  
 The device is specifically designed to increase efficiency and accuracy of delivery 
of Botox™ and other hypodermic injections. We are looking to improve the current standard of 
delivery and the basic syringe and hypodermic needle combination, so that the physician can 
focus his attention on depth dependent portion of delivery of Botox™ and other hypodermic 
drugs. The device aims to manage the multiple variables of drug delivery and will let the doctor 
focus primarily on accurate delivery with quicker, more precise treatments that provide longer-
term affectivity without the risk of improper muscle paralysis and other hazardous side effects 
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(Werner et al, 2006). For the specific needs of Dr. Naram, we will be focusing on the use of the 
device with Botox™ injections, though any syringe delivered drug may be possible. 
2.2 Industry Background  
Cosmetic and reconstructive surgery has been a long-standing facet in the halls of 
medicine. Starting with early reconstructive procedures in 1917, Cosmetic and reconstructive 
surgery has grown significantly in the last century to improve the lives of millions across the 
globe.  
With over 1.3 Billion USD in revenue, the industry continues to grow. The number of 
non-surgical procedures in the industry has gone up more than 500 percent from 1997 to 2013 
and approximately 6.1 million patients underwent Botox™  procedures just last year  (ASPS, 
2014). There is continued growth in the use of Botox™ for cosmetic purposes as the cost of the 
procedure decreases with improvements in affectivity and technique of injection. This cost 
decrease is also aided by the use of Botox™ for non-cosmetic purposes and potential health 
benefits the treatment has to offer.  
 
2.3 Botulinum Toxin Background and Use 
Botulinum Toxin is a highly potent neurotoxin produced by the bacteria Clostridium 
botulinum (Montecucco et al. 2005). Its first reported clinical use was discovered in the 1960s 
when Dr. Alan Scott started formulating a solution that would allow for the harnessing of a 
neurotoxin that can cause muscle paralysis. 
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Figure 1: Injection locations for BTX-A and dermal fillers (Ortiz, 2015) 
 By 1985, using extremely small aliquots of less than 1 μg, Scott was able to use 
Botulinum Toxin type A (BTX-A) to treat a patients with spasms of the eyelids and those with 
“crossed eyes,” a result of misaligned eyes (Flanders et al., 1987). As time went on BTX-A has 
grown into a multimillion-dollar industry within cosmetic and reconstructive surgery and nearly 
6 million patients undergo Botox™ procedures every year. Injections into the face make up 
much of the market for the drug and clinical uses abound. 
BTX-A was initially purified in 1928 by J. T. Snipe via isolation from its bacterial 
producer Clostridium botulinum (Snipe, P. et al., 1928). Its mechanism for disruption of 
neuromuscular disruption was subsequently isolated in 1949 by Arnold Burgen. Burgen’s lab 
found that BTX-A would completely disrupt transmission of the neurotransmitter Acetylcholine 
via completely inhibiting its release into the synaptic cleft. This stops the signal for contraction 
from propagating and as such causes muscle paralysis (Burgen, A. et al., 1949).  
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Botulinum Toxin is the most acutely lethal neurotoxin and retains a median lethal dose 
(LD-50) of 1.3–2.1 ng/kg intravenously and 10-13 ng/kg intramuscularly (Arnon, S. et al, 2001). 
Thusly, it is important that delivery is accurate and does not enter the systemic bloodstream. 
Retrograde injection of BTX-A has been known to cause facial paralysis and further paralysis of 
muscle function. During treatment if the user injects BTX-A into the patient too quickly the drug 
can push against the normal flow of the bloodstream resulting in transmission of drug up the 
blood stream opposite its intended direction of flow. This opposite flow of drug can place the 
toxin into large blood vessels that then deliver the toxin to unintended muscles. This makes it 
crucial to ensure a flow rate that does not cause a retrograde movement of dilute solution from 
small venules into larger blood vessels.  
Considerable research has been done to expand the use cases for BTX-A. BTX-A was 
initially used for treatment of Blepharospasm and Strabismus in 1980 (Flanders et al., 1987). 
From here the cosmetic and clinical uses would grow, allowing for use in treatment of 
hyperhidrosis (excessive sweating), chronic migraines,  and Raynaud's phenomenon 
(Neumeister, M. et al, 2009) (excessive pain in the hands due to reduced peripheral blood flow). 
BTX-A’s ability to function as an acetylcholine inhibitor is extremely efficient at relaxing 
muscle contraction and improving the above conditions.  
2.4 Current Methods of Delivery  
The equipment currently used for Botox™ delivery is a simple syringe and hypodermic 
needle (Naram, A, 2009). The needle, usually specialized 32 gauge hypodermics, for Botox™ or 
25-27 gauge hypodermics for steroids and hormones, are locked into the syringe. The syringes, 
normally 1-5 mL in volume, features a female Leur lok couple that locks onto the male Leur lok 
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couple on the needle (U.S. Patent No. US6074373, 2000). This allows for user safety and ensures 
that the needle is securely fastened to the syringe.  
 
Figure 2: Leur Lok interlocking parts (U.S. Patent No. US6074373, 2000) 
 The physician would then use this syringe and needle to load solution into the 
needle and remove any air from the system. This removal of air prevents introduction of air into 
the bloodstream, skin, or muscle. The handles of the syringe are held in the middle and index 
finger and the plunger is placed under the thumb. The physician would the place the tip of the 
needle within the skin, placing it at the needed depth for release of the drug.  
At this point some physicians aspirate the point of injection, making sure that no major 
blood vessels have been pierced, though there is some contention as to if all physicians 
delivering Botox™  actually perform this step of the procedure. After the patient dependent 
depth has been reached, the physician manually actuates the cylinder, delivering a per-patient 
specified amount of drug to the patient. This would then be repeated upwards to 20 times based 
on the patient’s needs.  
This holding method is one of many ergonomic problems with the current method. For 
many physicians this stretched position is uncomfortable and unstable. With average 
“comfortable” human thumb reach being around 2.25 inches the method is an uncomfortable 
overextension for many physicians (Otten, 2013).  
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Based on this repetition (Westerblad, H. et al, 1991), it is important to note that fatigue 
can affect the physician's ability to repeatedly carry out accurate deliveries of Botox™. This is 
why it is one of the goals to make an ergonomic device with which the physician can deliver 
pharmaceuticals. Fatigue can eventually manifest into physical limitations for the physician, 
from simple problems such as wrist pain to as severe as carpal tunnel syndrome. Performing 
repetitive hand movements can increase an individual's risk of developing carpal tunnel 
syndrome, making the condition highly likely for physicians whose job involves high repetitions 
of thumb and wrist motion (Terrie, 2010). If we can reduce the fatigue caused by these repetitive 
actions, we can increase the accuracy at which the physician can operate. This method has been 
used since the inception of the treatment procedure and has shown significant room for 
improvement. 
2.4.1 Existing and Alternative Devices 
There are numerous laboratory grade devices that are available on the market to deliver 
accurate volumes in the laboratory setting. There also is a current patent on a Botox™ delivery 
syringe (U.S. Patent US2006025902, 2006). This particular device encapsulates the, pre-loaded, 
syringe within the device and through the use of a driving mechanism, propels the syringe’s 
plunger in a stepwise manner. This allows the user to eject multiple aliquots or doses consistently 
and repeatedly. However, the main concern with use of these devices in a clinical setting is the 
lack of disposable parts and cost of custom syringe needle combinations. Within the clinical 
environment, concerns of cross contamination between patients and between batches of 
pharmaceuticals. Though labs do have these concerns, the sponsors would rather see a device 
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that would allow for use of conventional syringes and needles to be dropped in and actuated. The 
syringe would then be removed and disposed of in a sharps container.  
2.4.2 Laboratory Alternatives 
The current laboratory alternatives are very similar to the current standard in delivery for 
BTX-A. There are multiple options and makers, but all generally involve disposable tips, a 
plunger actuated delivery method and a selectable uptake and output amount. In particular, 
Sartorius produces an electronic pipetting device, titled, Picus® NxT. This device encompasses 
an electronic braking system in conjunction with a piston control system to control the accurate 
dispensing of liquid (Picus, 2014). This device also boasts an ergonomic and lightweight design 
and an aspirating function to reduce the amount of waste following use of the device.  
 
Figure 3: Picture of the Picus® NxT in action (Picus, 2014) 
Like many devices such as the device shown in Figure 3, a main concern and reason 
necessitating the design is that these types of devices are solely for laboratory use and not for 
clinical application. Aside from the incompatibility with clinical applications, there is a chance 
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that the internal volume uptake and deposition system of the device would come in contact with 
the solution and contaminate the device for use with different patients. This would require 
sterilization between uses, and would not be conducive to efficiency for a doctor with a large 
patient load. 
 
2.4.3 Analog Clinical Designs 
Filed as US patent US2006025902, Scott J Gerondale invented a single use fully analog 
device for delivery of Botox™ to a patient (U.S. Patent US2006025902, 2006). Though this 
device does meet some of the necessities of physicians that we interviewed, this would prove to 
be too costly to produce and use, and would likely increase the cost of the procedure past the 
already high 400-600 USD price per treatment.  
 
Figure 4: Design for single use ergonomic delivery device (U.S. Patent US2006025902, 2006). 
The device is designed to be held similarly to a mechanical pencil with the needle (16) 
facing downwards to the skin and fingers gripping the syringe on the syringe body (10). With the 
press of the index finger on to the release mechanism button (60) the plunger (74) would be 
lowered, depositing serum into the patient. This device is one time use and does not allow for the 
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movement of the plunger back up the barrel, because of this there is increased wastage of serum 
and material, forcing doctors to repeatedly buy this specialized and hard to make devices.  
The device intends to use the already available set of syringes and needles to deliver 
consistent doses and would require no additional repeated cost of supplies past the readily 
available syringes and hypodermic needles. 
2.5 3D Printing and Rapid Prototyping 
Three dimensional printing or additive manufacturing has allowed many companies and 
groups to rapidly prototype functional design elements. The additive manufacturing term was 
initially coined by Hideo Kodama in 1981 who developed a method for 3D printing that involved 
the exposure of a photo hardening polymer to UV light in masked of sections. This method has 
come to be known as stereolithography and can be employed to produce extremely accurate 3D 
models. However the monetary overhead and lead time can be prohibitive to operations that have 
a limited budget and time constraints, especially if they do not always need the accuracy offered 
by the stereolithographic method.  
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2.5.1 Fused Deposition Modeling 
 
Figure 5: Fused deposition method (Ghose, 2015) 
In the modern day, fused deposition modeling is used to achieve similar results, but with 
reduced overheads. In fused deposition modeling, a filament of polymer is heated and extruded 
through a ceramic head. Similar to the functionality of a hot glue gun, the polymer is deposited 
on a surface in subsequent layers, slowly forming layer after layer of connected polymer 
materials. This method produces a multi –layered object that is structurally stable in 2 out of 3 
axis, as seen in Figure 5, and performs well under compressive loading. This method is simply 
faster than the stereolithographic method and, because of its lower overhead, is easier to access 
for most of the populace. 
2.5.2 3D Printing Terminology 
Within the subset of the 3D Printing industry, a company called MakerBot makes build-
to-order 3D printing devices. These devices range in size and ability but in general allow for low 
cost creation of 3D models via fused deposition modeling. MakerBot offers 4 different printer 
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types and an amassment of different types of filaments in varying colors. To better understand 
3D printing terminology we have included a table of commonly used 3D printing vocabulary that 
can be easily referenced. 
Table 1: 3D Printing Terminology 
Word Meaning 
Boat 1st initial layers used to evenly adhere filament to build platform  
Build Platform Plastic is extruded onto this platform. Platform moves downward 
as new layers are to be extruded.  
Build Volume Printable area reachable by the extruder head 
Extruder head User-controlled heated die that melted plastic is extruded from.  
Filament Spool of melted PLA or ABS plastic with 1mm diameter 
Layer Height Height of the deposited layer, controlled by the extruder head 
MakerBot Replicator 2x 4th Generation 3D printer produced by MakerBot Industries 
MakerBot Desktop Software used to give instructions and build designs for use in the 
MakerBot Replicator 2x 
Support Structure Easily removable structure meant to support surrounding 
geometry 
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2.6 Analog Drive Mechanisms 
2.6.1 Ratchet  
The ratchet is a long standing mechanical device that allows for one way motion of a 
gear. In essence a ratchet has two main structures, an asymmetrical gear and a pawl. The gear is 
generally a sawblade-like gear that is anchored in its center via a tube or axel. The pawl is a 
small finger-like device that is spring-loaded to maintain constant contact with the gear.  
 
Figure 6 Simple pawl (a) and ratchet (b) mechanism (Band, 1894) 
 As you can see in the above figure, the pawl (a) prevents the gear (b) from spinning 
clockwise while allowing it to spin counterclockwise. When the gear is spinning 
counterclockwise the pawl slides over the face of the gear, pushing over the tooth due to its 
spring-loaded nature. If the gear was to rotate backwards, the pawl would catch on the steepest 
edge of the gear tooth and prevent any further motion. 
 When the gear is rotated in reverse the pawl must travel from the top edge of the tooth to 
the steep edge of the next tooth. This slight backwards rotation is called backlash and can 
prevent complete immobility of the ratchet during a reversal of motion. Its mitigation however is 
simple and can range from reducing the distance between teeth, to increasing the spring force to 
put greater pressure on the pawl to increase friction of the unit.  
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 This system is beneficial to the design process as it provides a unidirectional movement 
of the gear. Implementation into the device would provide a unidirectional drive for the 
deposition mechanism, making for a safer device and increased simplicity for users. 
2.6.2 Rack and Pinion 
A common linear actuator, a rack and pinion allows for rotational motion to be converted 
to linear motion. The mechanism employs a linear gear bar and a symmetrical gear.  In the name 
rack and pinion, the rack refers to the linear gear bar while the pinion refers to the circular gear.    
 
Figure 7: Rack and Pinion CAD drawing 
 Rotation of the gear/pinion engages the teeth on the gear bar/rack. This affectively allows 
the rotational force of the gear to be turned into a linear force applied by the bar (Sclater, 2013). 
Clockwise rotation of the pinion means movement of the rack to the left or upwards. While the 
counterclockwise rotation of the pinion means movement of the rack to the right or downwards. 
This mechanism has minimal backlash when the teeth are engaged as the teeth of both the gear 
and the rail are almost always engaged at a given point, this prevents back movement in the 
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mechanism and no inaccuracy in its desired range of movement (AGMA, 2005). The unit can 
however suffer from backlash upon initial insertion of the rail into the gear’s rotational radius. 
 The rack and pinion is a very simple machine and as such is very cost effective to 
implement. Creation of a mechanism with 3D printing can be quick and easy. Implementation 
into the device could provide a useful mechanism for conversion of a ratchet or geared button 
press into a linear up and down movement. 
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3 Project Strategy  
3.1 Client Statement 
To develop design plans and implement a design strategy we initially gauged the client’s 
needs with a written client statement. As we progressed through the project analysis and 
background research, the project was further able to define the scope and evolve the client 
statement to specifically meet the objectives of the client. 
3.1.1 Initial Client Statement 
Initially the team aimed to create an analog drug delivery device that would allow for the 
user to easily control the transfer of multi aliquot drugs to a patient. The team’s sponsor and 
client through the University of Massachusetts Medical Center in Worcester, Massachusetts, Dr. 
Aparajit Naram, expressed the need for this device in his clinic and wanted to design this product 
for future production and retail. To better understand the needs and objectives we approached Dr. 
Naram with an initial statement that would summarize his clinical needs and device objectives. 
The initial client statement was as follows: 
“The overall goal is to create an analog drug delivery device that will 
allow for depth dependent application of multi aliquot drugs to a patient. The 
device allows the user to insert a specific sized syringe into the device. The 
syringe is loaded into the device while holding down a “loading” button that 
“informs” the device of the starting size of the syringe with plunger. The device 
has a dial allowing the user to set a predetermined volume to be delivered which 
activates the device to drive the syringes plunger a distance specific to the 
volume. When the plunger is pressed the plunger will fully recoil to its full extent 
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allowing the plunger to be used to deliver the preset volume again. When the user 
is done, the syringe and needle can be safely and easily removed from the 
device and thrown away. The device itself never comes indirect contact with 
the patient.”  
- Initial Client Statement (9/04/2014) 
3.1.2 Further Analysis of Client Statement 
The original client statement, while detailed, lengthily described the specific design 
fundamentals of the device rather than explaining the client’s needs and overall objectives for the 
design of the device. The revised client statement needed to encapsulate an ideas that would 
address the objectives that Dr. Naram conveyed without including more design process oriented 
considerations. The statement concisely needed to mention: 
 Analog nature of the device 
 Quick and safe delivery of drug to patient 
 Efficient and accurate delivery of drug to patient 
 Ergonomic design of device 
 Accurate volumetric control 
 Minimization of drug loss 
The statement and goals needed to encapsulate these basic objectives to properly portray 
the client’s objectives as well as convey the project’s novelty as a clinical aid and medical 
device. 
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3.1.3 Revised Client Statement 
After further deliberation, research, and meetings with the sponsor the team was able to 
narrow down the client’s needs and objectives for the design and manufacturing of a drug 
delivery device. The revised client statement demonstrated the sponsor’s specific needs of a 
device that can perform specific tasks accurately and efficiently: 
“The sponsor would like an analog hypodermic drug delivery device that 
allows for quick, efficient, and accurate delivery of multi aliquot 
pharmaceuticals to the patient. The device is to be ergonomic and aid the 
physician in accurate placement and volumetric control of drug application 
while minimizing drug loss.”  
-Revised Client Statement (10/02/2014) 
The client statement was better able to encapsulate the overarching goals of the device 
and was able to portray the role of the device within the clinical environment. By working with 
Dr. Naram, the project team was able to better identify the novel features of the proposed device 
in comparison to the current “gold standard” methods.  
3.2 Identifying Design Objectives 
After identifying the client statement, we moved towards fleshing out the sponsor’s 
objectives into broader categories of information. The project team was able to categorize the 
objectives into two key categories. The primary objectives were formed to address Dr. Naram’s 
most important goals that he laid out in the initial interview. The secondary objectives were laid 
out to support the overall design of the device and further detail the facets of the initial design 
objectives.  
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3.2.1 Initial Objective Identification 
Through weekly meetings with Dr. Naram, the design team was able to agree on 
functionalities of the device through examinations of the Client statement. 
 
Figure 8: Objectives tree organized by overarching category 
The goal of the development of this objective tree was to give direction to the 
requirements of the project. The project team used it as a basis for developing the primary and 
secondary objectives and were able to use its branches as descriptors when talking to the 
client/sponsor. Using the listed objectives as a basis for discussion, the project team was then 
able to form and populate a pairwise analysis chart.  
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Table 2: Pairwise Analysis of Design Considerations 
 
Dr. Naram populated the chart with his answers and the totals were tabulated. The team 
was able to focus their priorities on various design concepts. Safety and reliability of the device 
was of the utmost concern; this was closely followed by user friendliness.  The team did not rank 
the secondary objectives further and allowed the conversations with Dr. Naram and client 
statements to drive decision making in regards to importance of secondary objectives. 
3.2.2 Re-evaluation of Device Objectives 
It can be noted that the Dr. Naram was more interested in the aesthetics of the device than 
the precision. The team came to the conclusion that there was considerable overlap between 
reliability and precision with little difference in key secondary objectives i.e. reproducible 
accuracy.  
There was considerable misunderstanding as to how the options were presented; though 
precision of uptake and deposition definitely mattered, these were viewed as secondary to the 
device’s ability to accurately dispense drug and reproduce said results, as denoted in the initial 
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objectives tree. The objective tree was then remade, specifically to combine these two primary 
objectives. 
 
Figure 9: Updated objectives tree showing Primary and Secondary Objectives 
The objective tree was pared down significantly, removing overlapping statements in 
ergonomic use and reconstituting reliability to consist of both the precision and reliability 
primary objectives of the previous trees. We also removed more obvious secondary objectives 
such as useable design in the aesthetics primary objectives. 
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3.3 Primary and Secondary Objective Extrapolation 
The primary objectives were made using the updated objectives tree found in Figure 9. In 
total, after revision of the objectives tree, the project had five main objectives: 
 Safety of the device 
 Reliability of the device 
 User friendliness of the design 
 External aesthetics of the device 
 Cost of the device 
The objectives are listed and discussed in that specific order that Dr. Naram  
3.3.1 Device Safety 
Because the device is for use with active pharmaceuticals, it was deemed necessary that 
the device be operated as safely as possible and present any risks to the patient or the doctor. 
3.3.1.1 Physical Safety Fail Safes 
 It was very important to Dr. Naram that there were fail safes in place to prevent over 
delivery of drug to the patient as this can cause paralysis of areas around the injection site. The 
project team also wanted to ensure that it was not possible to introduce air into the blood stream, 
reducing the chance of damage to arteries and tissue in the area of injection. 
3.3.1.2 Contamination Prevention 
As this device is also to be used very frequently within the span of a day, the project team 
wanted to ensure that the device did not come into contact with any patient bio fluid, active 
pharmaceutical, or other biologically contaminating source. This is the basis for the project team 
using designs that employed a system that uses existing syringes that can be thrown away 
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without contaminating the device’s internal systems. With this in mind, the client wanted to be 
able to wipe the device down with isopropyl alcohol between uses as the only of sterilization. 
3.3.2 Reliability of Design  
On the pairwise analysis chart, the sponsor ranked reliability on the same level as the 
safety of the device. After reforming the tree and including the previous precision branch of the 
tree, the project team was able to concisely categorize objectives that dealt with the accurate and 
precise deposition of pharmaceuticals by the device.  
3.3.2.1 Simplicity of a Completely Analog Design 
By working with Dr. Naram, the design team identified the necessity for a mechanically 
driven option for hypodermic injection. This design objective was stipulated to underline the 
necessity for a simple easy to use device that would reliably perform over and over again, 
without repeated input. 
We also considered that the response time of a fully mechanical device would be 
considerably less than that of an electronic one, thus allowing for repeated use without having 
wait for the added start up, batteries, and limited use times inherent with electrical devices. 
3.3.2.2 Accuracy and Precise loading and deposition 
Due to the multiple aliquots nature of Botox, multiple volumes of solution are injected 
into each patient. The device needed to able to repeatedly (precisely) and accurately dispense the 
user-determined volume of drug per aliquot. The project team aimed to test the viability of the 
uptake and deposition mechanism while it is external to the device, and then repeat viability 
testing while the system is within the device to ensure optimum performance. The project team 
wanted to ensure accuracy of volume deposition for all steps in the design and make sure that the 
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system is accurate outside of and within the device. The project team sought to compare 
performance to a lab grade analogue by comparing volumetric output at a given set point.  
One of the many problems with the current method of hypodermic drug delivery is the 
unreliable flow rate upon injection of solution into the patient. This can become a serious 
problem if the user accidentally injects a drug solution too quickly into the patient. For example, 
injecting a solution of Botox™ too quickly can cause retrograde injection of the drug into the 
patient’s blood stream. This increases the possibility of paralysis, blindness, and other major 
health complications. 
3.3.3 User Friendliness of Design 
The next highest rated objective was user friendliness of the device. This user friendliness 
was encapsulated in ensuring that the device had an ergonomic design, was able to give feedback 
during use via audible cues, and must allow for quick loading and unloading of syringes of 
varying size and volume. 
3.3.3.1 Ergonomic Design 
Through personal communication with the client, Dr. Naram, it was concluded that the 
ergonomics of the device design was an imperative. In essence, the device needed to be easy to 
handle for the user. This was important because over the course of a single day a user may see 
upwards of twenty patients, and depending on the particular needs of the patient a single session 
can last 15-20 minutes. The current method of drug delivery, use of a syringe and needle, has a 
tendency to cause fatigue in the user over extended use and treatment sessions. The design is 
aimed to alleviate the user’s fatigue and prevent any errors that can be attributed to fatigue. 
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To accomplish this the client has expressed a need for the device to fit comfortably 
within the first web space of the user’s hand. This means that the device would be placed 
between the thumb and the index finger much like the form of a pencil. This positioning would 
allow for ease of use and accurate placement of the hypodermic needle, allowing physicians to 
repeatedly inject the control volume at the correct positions and depths over long periods of use. 
The project team planned to have an initial ergonomic concept that was present to Dr. Naram for 
his thoughts. The project team then developed the product through iterative redesign based on 
the feedback of the UMASS physicians and plastic surgeons. 
3.3.3.2  Reusable and Versatile Design 
Through the background research and correspondence with Dr. Naram, the project team 
recorded the application of Botox™ through varying gauge needles and syringe volumes. Taking 
this into account, the design will be able to use common syringes of 1-5 mL in volume delivery 
and allow for accurate deposition of active pharmaceuticals through 25-32 gauge hypodermic 
needles. This allows the device to accommodate different practices that use a varying 
manufacturer of syringes and hypodermic needles.  
Because the device is reusable within the clinic and between patients, it must obviously 
never come in contact with any active pharmaceuticals or patient bio fluids. Within the 
stipulations of Dr. Naram, the device will be readily cleanable with isopropyl alcohol or any 
other antibacterial product. As there is no need for sterility of the device, there is no need for 
further cleaning or autoclaving.  
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3.3.3.3 Device Feedback 
As seen in the pairwise analysis chart in Table 1, the sponsor would like to have a very 
user-friendly device. Dr. Naram would like to see a method of notification and user feedback for 
different aspects of the device use and drug delivery process.  
To increase user friendliness the sponsor would like to have the device provide some sort 
of feedback for when a single aliquot is complete or the syringe is empty. Feedback would 
improve user accuracy and patient to doctor interactions. This would play a key factor in safety 
of the device, and overall marketability to physicians. 
3.3.4 External Aesthetics 
The 4th highest objective in the pairwise comparison chart was the Aesthetics of the 
device, specifically the color and shape. This objective focuses in on the need for the device to 
marketable to plastic surgeons as a method of more accurate delivery. This means that the device 
must provide function and form, and as such the external shell will have to not only be 
ergonomic, but must add to the appeal of the device.  
3.3.5 Cost and Marketability 
The cost of the device will be very dependent on the internal components. The overall 
cost to produce a device will be lower for a fully mechanical device than a device that uses, 
batteries, LCDs, and drive motors. This reduction in costs plays directly into marketability. If a 
device that is accurate to the needs of a physician can be produced for a lower cost, it can be sold 
a lower price point. The device aims to be cost effective; it is with this cost effective design that 
Dr. Naram intends to drive sales of a final product.  
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3.3.5.1 Post-injection Drip Drug Loss 
While keeping a consistent volume per injection site is important for safety and patient 
satisfaction, the device will also save small amounts of the drug in the barrel being wasted by run 
off or minute over-injection. Following a single injection a phenomenon occurs in where there is 
drug loss due to post-injection drip. This occurs at some level after each injection and over the 
course of one treatment session can add up to a significant amount of waste. This runoff is likely 
induced by capillary action caused by removing the needle from the patient’s facial tissues.  
The sponsor has communicated to the project team that, while this may be a difficult area 
of waste to overcome, he would like to see the device negate this form of loss. According to the 
research and discussions with Dr. Naram, over the course of a single session the patient and 
physician may see savings upwards to 80 USD; this savings can not only help market the device 
but can help patients a more effective treatment for the cost. 
3.4 Constraints 
Through further development of the objectives we categorized the constraints into three 
main areas: Safety, Manufacturability, and Usability. Using these categories, the project team 
were then able to further expand the objective tree, focus discussion during meetings with the 
sponsor, and build criteria for gauging affectivity of designs. 
3.4.1 Safety Constraints 
Safety of the device was of the utmost concern, as Botox™ is a very strong neurotoxin if 
used improperly. Because of this the device: 
 Must be sanitized with isopropyl alcohol 
 Not be able to come in contact with active pharmaceuticals or bio-fluids 
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3.4.2 Manufacturing Constraints 
The goal of this project is to offer a final prototype that can be used for further 
manufacturing. This means that we must have taken into account design of the device for future 
manufacturing via extrusion/machining/molding.  
 Ergonomic design that reduces yield loss of materials 
 Material used is wear resistant and economical for production 
 Tolerances within device manufacturing do not require high precision machining 
3.4.3 Usability Constraints 
Working with the project objectives the project team identified the need for numerous 
constraints and guidelines for usability. These constraints were taken from the interviews with 
Dr. Naram and were extrapolated from his initial design documentation that he provided. 
 Ergonomic one-handed design  
o Must be placed in the first web space 
o Must not cause fatigue over long periods of use 
o Cannot interfere with repeated injection of hypodermic needles 
 User defined volume delivery 
o Must give accurate results with low variance (±5%) from the set value 
o Must deliver solution at rates lower than that of peripheral arterial blood flow (<.1 
cc/sec) 
o Must not block site of volume left in syringe 
 Simple exchange of syringes and needles 
o Must allow for sub 20-second removal and replacement of spent syringes/needle 
combinations.  
40 | P a g e  
 
o Must allow use of 1-5 mL syringes and 25-32 gauge needles 
These constraints were used as a driving force for innovation in the design. As the project 
progressed most constraints were kept the same unless otherwise noted.  
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4 Initial Designs 
To begin work on the project initial concepts we used Solidworks to conceptualize 
designs. The goal of these initial designs were to field initial reactions to certain shapes, sizes, 
and hand placements for the device. Key concepts in these devices included: 
 Easy initiation and termination of injection 
 Pencil like-grip 
 Holder allows easy access to syringe 
 Visible syringe volume 
 Holder allows for variable syringe volumes 
Keeping these initial stipulations in mind the project team worked to design the following 
ergonomic outer shells. These shells were presented in their electronic form to clients for review. 
After their review, the comments for each device were noted and further stipulations and design 
ideals were fleshed out. 
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4.1 Dumbbell Device  
 
Figure 10: Initial Ergonomic Dumbbell Device 
This initial device was meant to be held much like a pen. The device shaft would lay 
within the first web space and delivery of a specified volume of drug would be triggered via a 
press of the index finger. The device employed the use of a delivery volume window to allow for 
ease of viewing of the syringe as it was used by the device.  
The ergonomic shape of the device provided three distinct surfaces for resting of the 
thumb, index, and middle fingers, similar to ergonomic pen grips found on modern pens. 
Syringes would be placed inside by opening the device in a clamshell fashion, and placing the 
syringes within a predetermined area of the shell. Because this was such a rough model the 
design facets that the design was intended to meet were weighted towards ergonomic 
possibilities and not towards possible mechanisms designs 
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4.2 Wedge Device 
 
Figure 11: Initial Ergonomic Wedge Design 
This initial device was also meant to be held like a pen. The device would be held flat 
with index finger on the left face, thumb on the right face, and index finger supporting the device 
tip from the bottom. The upper part of the body (farthest away in Figure 11) was meant to rest on 
a user’s first web space and provide greater surface area for finger contact. The shape also 
included an injection volume window and syringes would be placed inside via a clamshell like 
opening of the device. The focus of this design was to gauge the client’s liking of different shell 
shapes and aesthetics.  
4.3 Initial Design Client Feedback 
The project team brought the devices to the client seeking feedback on ergonomics, 
design choices and further sought to formulate design facets. In doing so, the client was able to 
give the project feedback and better steer the design process.  
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Though the dumbbell device shell did meet some client needs, there were some problems 
with this initial device. For example. The pen like grip made mechanical drives extensively hard 
to design, and created unsurmountable problems within the already tight internal space 
constraints of a hand held device. 
This wedge design, much like the dumbbell device, had considerable drawbacks. The 
device was significantly less ergonomic than needed though it provided increased internal space 
for mechanical drive systems. The grip was initially considered greater to that of the dumbbell 
device but the device would not be a good one-size fits all use for various sizes of physicians’ 
hands. 
The client feedback also gave cause for refocusing design efforts. From Dr. Naram’s 
comments and feedback a new design constraint was implemented. Not only did the analog 
device have to be held within the first web space, but it also was meant to be held upright in the 
same manner used by pipettes. The first iteration design had been focused on pen like devices 
that would not have met the client’s needs and would have been increasingly hard to design. 
Refocusing efforts onto a more upright pipette like device opened up new options for device 
design. The new goal was to take the previous design facets that had worked for the initial 
designs and apply them to a new upright device. 
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5 Second Iteration of Design 
Based on the feedback from the client there was a necessity for a significant redesign. 
The client wanted the scope of the project to focus on an Ergonomic design for repetitive day in 
and day out use of the device. The stability of the device within the first web-space was also key. 
By moving towards an upright design for the device, similar to lab grade pipettes, future 
conceptual designs would be better able to provide first web-space stability while also providing 
ergonomics for reduced fatigue.  Using these new design parameters the project moved forward 
into a new iteration of design. 
5.1 New Design Concepts  
 
Figure 12: Initial Concept for Second Iteration of Design 
Adhering to the stipulations mentioned previously, a new conceptual idea for the device 
was created. Figure 12 shows a cross section of the proposed device with color-coded sub-
assemblies. Main features in this new design are an introduction of a ratcheting drive 
mechanism, a new mechanism for loading the syringe and a new ergonomic design.  
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5.1.1 Drop in Syringe 
In the previous figure, the syringe is shown in blue. It is meant to be loaded into the 
syringe from the top, removing the need to open or close the device like in previous design 
iterations. This drop in method would allow for greater safety to the physician or physician’s 
assistant and would require less cleaning of the device as less internal volumes of the device 
would be exposed to the patient clinical environment.  
5.1.2 Introduction of Drive Mechanisms 
In Figure 12, the drive mechanism is shown in red and purple. This proposed mechanism 
is similar to the rack and pinion and ratchet systems described in chapter 4.  As the red plunger is 
depressed, so too is the plunger on the syringe to which it is attached. The mechanism only 
allows for one way movement and this adds some safety to the design, as it prevents air from 
getting into the injection if the plunger were to be reversed. This method also prevents the 
surgeon from moving the mechanism backwards without his/her knowledge, preventing the over 
or under injection of serum and increasing the physician’s efficiency. 
This ratcheting mechanism also benefits the device by preventing loss of serum on 
removal of the device from skin. Within the client’s initial requirements was a necessity to 
prevent post injection drip. By preventing the movement of the plunger after removal of the 
needle from the patient’s skin, the post injection drip is mitigated. 
5.1.3 Ergonomic Design 
The black outline in Figure 12 shows the basic silhouette of the ergonomic shell of the 
device. This design was made to feel similar to laboratory grade pipettes and included features 
like an index finger catch and a rest for the first webs-space and thumb. The design was to work 
in an upright fashion with the thumb on the red plunger and the rest of the hand wrapped around 
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the device similar to the method shown in Figure 3. Through the client feedback the design team 
knew that this was a design facet that needed considerable refinement but saw this initial design 
as a good starting point for further revisions and iterations. 
 
Figure 13: Top down Cross-Section of Ergonomics Shell 
Further design consideration in this stage were also made for design of the shell’s barrel 
shape. The mid portion of the device was to be shaped in a way that provided better grip and 
comfort than that of a square piece of stock. Cross section A was shaped to mimic the shape of a 
can or pill bottle. Cross section B was shaped to mimic that width of a telephone. Cross section C 
was made to be a combination of the two featuring a design similar to current market laboratory 
grade pipettes (Picus, 2014). 
By presenting these design options to the clients, the design team was better able to build 
out clay models for their consideration. The three cross sections shown in Figure 13 show the 
proposed shapes. These shapes were proposed under the pretense that their rounded nature would 
provide better contact area with the physician’s hands and would be easier to grip than a square 
or tubular structure.  
  
A B C 
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5.2 CAD Modeling of Second Iteration 
 
Figure 14: CAD model of second iteration at initial (A) and intermediate (B) extension 
By extrapolating the concept design for the device, the project was able to produce CAD 
models in PTC CREO Parametric 3.0. This software allowed the design team to change 
ergonomic facets in a fashion more simple than Solidworks allowed, and as such allowed the 
project to tailor designs to the client’s needs much quicker than previously thought.  This 3D 
model also served in giving the design team a better understanding of the internal volumes of the 
device. 
A B 
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Through CAD modeling the project team was also able to show how the proposed 
mechanism would work. As shown in Figure 14, a 1 inch movement of the device plunger from 
(A) to its final position in (B) produces a 1 inch movement in the syringe plunger. This device 
design succeeds in changing the location of the thumb place to an area closer to the syringe body, 
allowing for better control of the device and more comfortable ergonomics.  
 
 
Figure 15: Closer look at syringe insertion point 
The CAD model also provides a better look at the drop-in syringe design as well as how 
the ratchet/rack and pinion drive mechanism works, as you can see in Figure 15. The CAD 
model also afforded the project team the ability to begin 3D printing a model for use as a proof 
of concept piece.  
  
50 | P a g e  
 
5.3 3D Printing of Device Shell 
Printing for the device was managed done on a MakerBot Replicator 2x. This device 
featured a possible 100 micron resolution and 9.7” x 6” x 6.1” possible build volume, making it 
ideal for uses in prototyping the design. By converting the CAD model into point data the project 
team was able to place the design into MakerBot Desktop, and then print it on the MakerBot 
Replicator 2x using the following parameters. 
Table 3: MakerBot Replicator 2x Print Settings 
Parameter Input Value 
Filament Type MakerBot ABS 
Extruder Temperature 230 °C 
Build Plate Temperature 115 °C 
Resolution Preset High (.15 mm Layer Height) 
 
These parameters were based on initial print parameters set as default to the device. Small 
changes to extruder temperature and build plate temperature were made to better adhere ABS 
boats made under each device shell. Full procedures can be found in Appendix A section 9.1 
Procedure for Printing of CAD Model. Initial prints failed repeatedly due to filament feeder 
malfunctions and creep caused by the heated plate and slower deposition rate caused by higher 
resolution. This was combatted using a slurry of acetone and ABS recommended by Anthony 
D’Amico of Peterson Lab. This slurry allowed for better bonding of ABS to the build plate while 
reducing the creep caused by the heated plate by creating a small barrier layer of ABS slurry that 
acted as a buffer layer. Procedure for Slurry creation can be found in Appendix A section 0   
51 | P a g e  
 
Procedure for ABS Slurry Creation. 
 
  Figure 16: 3D printing of second iteration design 
This printed device shell was made in two parts to show the potential inner workings of 
the device via presentation of the lateral cross-section of the device. When put together, the shell 
also showed a potential final size and ergonomics of the device. These models were brought to 
the client for feedback and detailing potential future changes. 
5.4 Clay Modeling for Ergonomic Design 
After the initial devices were shown and discussed with the client, focus was turned to the 
ergonomic design. The shell would dictate the ability to implement mechanical drive systems 
and would in essence drive device creation. Because of this, the project team needed to ensure 
that the ergonomic design was comfortable for the physicians.  
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To achieve this goal of ergonomic comfort, the design team formed multiple clay model 
shell designs. They used shapes similar to the cross sections found in Figure 13 to offer a better 
baseline for ergonomic shell design. To make these clay device shells, modeling clay was 
procured and shaped into tubes of 1.5 inches in diameter and 5 inches in length. A scaled cut out 
of Figure 13 was placed on the cross sectional face of each tube and the tube was then molded to 
each shape. A cap was placed on each piece resembling the upper portion of the second iteration 
design. A clay model of the actual device was made as well to further aid in rapidly changing the 
ergonomic layout. Each of these designs was then presented to the client for feedback. 
5.5 Second Iteration Client Feedback 
User feedback for the second round of devices was positive and provided a progressive 
method for creating the final iteration of the device. Using the models, the design team were able 
to gauge the design on ergonomics, drive functionality, balance and aesthetic appeal. These four 
categories would be employed to further drive change within the device and these parameters 
also relate back to the initial design concepts seen in Figure 9. There were a number of take away 
messages from this round of client feedback and the new design parameters provided the design 
team with pertinent feedback that better aided the project team in creation of the final shell and 
drive devices.  
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5.5.1 Ergonomic Feedback 
 
Figure 17: Clay model testing of the ergonomics of the second iteration design 
The ergonomic feedback the shell received was beneficial to reshaping the device. The 
project team first approached the client with the clay mockup of the design pictured in Figure 17. 
The project team immediately realized a key concept that the design lacked. The ergonomics of 
the device did not readily suggest how it was to be held. This meant that, as a new user, surgeons 
like Dr. Naram would not be able to hold the device properly. In fact in the above figure, Dr. 
Naram is incorrectly holding the device. His thumb is extended when it should be placed on the 
plunger featured lower on the device. In Figure 17, the client’s index finger is above the index 
finger catch instead of the intended location of under the catch. After this misinterpretation of the 
devices ergonomics, it became an imperative that future designs have more obvious placements 
for the thumb and index finger, to prevent misuse of the device by a new user. 
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From use of the clay shell models the project team were also able to better understand 
how the barrel shape made a difference to the physician. Ideally, the device would fit firmly in 
the first web space with consistent contact though the palm and a slight tapering as it sits within 
the hand. The assumption was underscored as the project team proceeded through the feedback 
with Dr. Naram. From the shapes mentioned in Figure 13, the first two received negative 
feedback as they were too small to be placed in the hand and stay stable, the first oval cross 
section, or too large and sharp without enough taper, the rounded square cross section.  
The third cross section received favorable feedback. The taper designed allowed for 
continuous contact with the hand and allowed Dr. Naram to easily balance it within his fingers. It 
was noted that the client also wanted to place his index finger above the index finger rest instead 
of underneath. IT was also noted that the slightly rounded front and rear of the design aided in 
keeping the device firmly gripped within the hand. 
5.5.2 Drive and Volume Delivery Design 
The feedback for the volume delivery portion of the device was greatly beneficial in 
steering the project away from the 1:1 movement ratio design mechanism. Because a one inch 
movement on the device plunger meant a one inch movement on the syringe plunger, the design 
was really only moving the positioning of the hand and thumb while keeping the large range of 
motion needed to administer a dosage. The design team also surmised that keeping the same 
large range of motion would likely continue to exacerbate the pain and discomfort caused by 
fatigue of repeated injections.  
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6 Final Design 
The final design was broken into two separate designs. The first was the ergonomic shell 
of the device. The second was the drive and volume delivery mechanism of the device. Both 
were conceived with the constraints the other may have in mind.  
6.1 Ergonomic Device Shell 
 
Figure 18: Final design for ergonomic device shell 
The final design for the device shows many of the device facets exhibited in the previous 
design iterations while addressing the previous design problems that the design team face in the 
initial and second iterations. There are six key design features that the design revolves around: 
 Index Finger Rest and  Placement 
 Thumb Rest and Placement 
 Ergonomic Design 
 Volume Window 
 Syringe Drop In 
 Fitting a Ratcheting Design 
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The index finger is placed on the top of the bump featured on the front of the device. In 
the previous design, the client had mistakenly pinched the index finger rest between his index 
and middle finger, offering him more stability when using the device. The design team carried 
this device facet forward and placed it in such a way that it lined up the index finger and base of 
the thumb on the shell. This focus a single style of grip getting rid of the previous confusion 
associated with the design.   
The index finger rest also allows for better control of the devices rotation and movement 
in space. By pinching the finger rest between the proximal phalanges of the index and middle 
finger, users can prevent movement and slippage of the device. 
The thumb rest and thumb placement is partially dictated, as previously mentioned, by 
the index finger placement. The first web space can be placed readily under the thumb rest and 
can be removed when the physician seeks to inject the volume.  The trigger is rounded to 
comfortably fit and work under the pressures of repeated depression by the thumb. 
 
Figure 19: Final design section view of ergonomic shell 
The Ergonomic design is taken form the feedback received on the clay models the design 
team created previously. This design is similar to the last section view seen in Figure 13, and has 
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been compressed slightly to better meet the ergonomic needs of the client and fellow surgeon. 
This design provides a greater usable surface area, increasing stability in the hand, and fits well 
within the volume that the hand can comfortably control. 
The volume window was a design facet that continues from the first iteration of designs. 
The client always wanted to be able to see how much of the device volume has already been used 
and this window prevents the physician or surgeon from having to guess how much serum they 
have injected over the course of the treatment. This window increases safety for the patient and 
provides peace of mind to the surgeon or physician who is delivering injections using the device.  
Syringe drop in was carried over as a design facet from the second iteration device. This 
design facet makes loading and unloading of the syringe significantly easier and prevents 
potential internal contamination of the device as it no longer requires the device to be open when 
exchanging syringes. It also reduces the time needed for reuse of the device after expenditure of 
an initial syringe. 
Design concepts for the internal volume deposition mechanisms had to be kept in mind 
while designing the shell of the device. The upper portion of the device was developed to 
comfortably house any such mechanism by having a wider and more spacious upper end than in 
previous designs. With this space in mind, an internal mechanism was developed that would 
safely and efficiently fit within this space. 
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6.2 Ratchetting Drive Mechanism 
 
Figure 20 Ratchet Mechanism Design 
 By adopting a ratchet like design for the driving mechanism, the user cannot turn a push 
of a button into the downwards movement of the plunger. The mechanism works similar to that 
of a normal ratcheting trailer hitch, except one side is not fixed and a spring now prevents the 
over extension of the device past the limits of the device. In essence, the ratchet can only move 
one asymmetrical tooth at a time, allowing for only one aliquot to be delivered per gear press.  
 To achieve syringe plunger depression, the ratchet was coupled with a rack and pinion 
like rail set up. This set up allowed allows the device to change the rotation of the gear in the 
middle of the ratchet device into the downward movement of the rail. 
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Figure 21: Ratchet and rail combine to depress plunger 
Every time the button is depressed the casing moves downward. The spring tensioning of 
the casing then pulls the assymetrical wheels of the ratchet up as the pawl is now engaged. When 
the pawl is engaged, the gear around the center of the ratchet seen as a beige tubular gear in 
Figure 20, spins clockwise, pulling the rail down and with it the syringe plunger.  
This method also offers safety to the doctor. Because the movement of the syringe 
plunger only begins when the casing is lifted (after the the button is pressed and allowed to 
return to its initial position) the Surgeon can avoid misinjections by not letting go of the button. 
This way if it is accidently pressed while in the incorrect position, the position of the needle can 
be corrected and the contents then released. The button also cannot be partially pressed as it 
would then return to the start position without disengaging or reengaging the ratchetting system 
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6.3 3D Printing of Prototype 
 
Figure 22: Printed Shell of final ergonomic design 
Printing of the prototype shell was achieved via methods described in Appendix A using 
the presets found in Table 3. This model featured only shell components and no components 
from the mechanical volume deposition mechanism. The model was initially printed on a boat to 
promote even adherence to the print surface, and support material was used to procure an even 
print. Both boat and support material were then sanded down and removed.   
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6.4 Proof of Concept Model 
A proof of concept model for the mechanism was built to provide a basis for future 
design and production. The project was limited by the resolution of the 3-D printer and the 
creation of device size model wasn’t possible. To prove that the concept worked and provided an 
efficient methods to meet the goals the concept was built in 2:1 scale. 
 
Figure 23: Proof of Concept Model showing the ratchet functionality of the deposition mechanism 
Rail position indicated by orange bar 
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 As shown in Figure 23: Proof of Concept Model , the model functions and displays the 
method of interactions that the ratchet design uses to achieve the plunging of the device. A single 
press of the scale proof of concept model’s lever is tantamount to a single aliquot being delivered 
to the patient.  
7 Conclusions and Future Recommendations 
7.1 Ergonomic Design 
The goal for an ergonomic design was to develop a product to aid a physician in accurate 
hypodermic injection administration. The idea was to employ a design that allowed for a simple, 
comfortable, and intuitive injection experience. . To aid in the process of developing ergonomics 
clay models were made to better understand surgeon preferences and grip sizes. Rapid 
prototyping via 3D printing was employed to rapidly create models and scale replicas of the 
ergonomics. Through multiple iterations of device shells, a final shell was settled upon. 
The final design created, employed all the design facets that were discussed throughout 
the iterative design process. These include, ergonomic design, volume delivery window, and 
easy to use press button location and an overall simple and safe design. The design proposed can 
also still be tweaked using CAD software such as Solidworks or PTC CREO Parametric 3.0, and 
as such will continue to get ergonomic updates as feedback from the client continues. 
Future updates to the design of the shell will be dictated by further physician input, and 
will be carried out at the availability of surgeons at UMass Medical. Improvements to the design 
can then be handled within the CAD Software based on the already available files as mentioned 
above.  
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7.2 Volume Deposition Mechanism 
The goal for the volume deposition Mechanism was to safely and accurately deliver acute 
quantities of serum to a patient at the press of a button. The Strategy was to employ a design that 
allowed for a simple and accurate mechanism, which would have some feedback for the surgeon. 
Through rapid prototyping and iterative design a deposition mechanism was made by coupling a 
ratcheting mechanism to a rack and pinion like device. Together this mechanism offered a 
simple, safe and adjustable way to deliver volumes of drug to a patient.  
 
Figure 24: Common printing defect at small scales 
Further improvement of this design will come from an improvement in 3D printing. The 
current method is limited by accuracy of the 3D printing head in terms of making small gear 
teeth and material walls. The gear shown in Figure 24 for example shows a wavering and 
inconsistent wall structure for the asymmetrical gear used in the ratchet device. The resolution 
for these prints was increased from a layer thickness of .15 mm to .10 mm. Even with these 
resolution increases, the produced pieces did not have the required shape or sturdiness needed. 
These problems were difficult to overcome in the short period of time provided within the scope 
of the project and will have to be left to future iterations to fix. By creating these parts in more 
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accurate 3D printers, smaller pieces would be possible and a full scale down of the mechanism 
would be attainable.  
7.3 Further Testing 
Further testing would have to be carried out to substantially flesh out the device’s use 
parameters. Because of the problems with scaling down the drive mechanisms, no tests have 
been done to quantify the accuracy of the mechanism at scale. Though the mechanism does 
display great promise in its reproducibility and consistency of movement, further testing of the 
device on skins and hydrogels would allow for further quantification of the abilities of the device 
at scale.  
Due to the limitations in filament types (ABS plastic only), choosing the device materials 
was also pushed out of the scope of this project. However, in the future this aspect could 
definitely be addressed. Considerations in design have already been made for replication with 3D 
printers and considerations would have to be made when switching to injection molding. 
Material choice would also have to be taken into consideration as ABS is not safe for use with 
common cleaning solutions of alcohol and would not be FDA approved (Food and Drug 
Administration, 2014). 
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9 Appendix A 
9.1 Procedure for Printing of CAD Model 
1. CAD models were exported from Solidworks/CREO Parametric 3.0 in the .STL file 
format. 
2. MakerBot Desktop software was started and allowed to load 
3. .STL files were then imported into the MakerBot Desktop software via the ADD FILE 
button. 
4. If prompted by software objects were moved to the platform 
5. If needed objects were rotated to the correct orientation of printing 
6. If multiple objects were printed, steps 1-5 were repeated. 
7. Objects were positioned on print bed with ample space between objects using the 
movement tools. 
8. Setting were calibrated using the SETTINGS Buttons 
a. MakerBot ABS was selected for the left nozzle 
b. MakerBot ABS was selected for the right nozzle 
c. Color-Matched was selected for the Raft and Supports 
d. A appropriate resolution was selected for the object to the printed 
e. If high was selected Advanced options button was clicked 
i. Under quality layer height was set to  the appropriate value  
ii. Under temperature the Left and Right Extruder temperatures were set to 
230°C and the build plate was set to 115 °C  
f. Save settings was pressed 
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9. File was exported using the EXPORT PRINT FILE button 
a. File was allowed to load 
b. Print Preview was selected to ensure no improper geometry was seen 
i. If print preview was incorrect, step 7 was repeated and then step 9 was 
tried again. 
ii. If print preview was correct, the window was closed using the Close 
button 
c. File was exported using Export Now button in the Export window. 
i. File was saved as .x3g file type to SD card used with MakerBot System 
10. SD Card was placed in SD Card slot for MakerBot 
11. Build from SD Card was selected on MakerBot 
12. Using the up and own arrows, the correct file from the SD Card is selected 
13. Print is initiated via pressing the central OK button. 
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9.2 Procedure for ABS Slurry Creation 
1. .5 gram of scrap ABS extruded filament is weighed on a scale 
2. ABS is crushed and broken via folding and placed into a 100ml beaker 
3. 60 ml of acetone is added to the beaker 
4. 5 minutes of time is elapsed to allow for the melting of the ABS into the acetone 
5. Slurry is mixed using glass rod until mixture is evenly off white in color 
a. If pieces of ABS are still present, additional acetone may be added until pieces are 
dissolved. 
6. Slurry can now be dabbed on to surface of kapton taped build plate via Kimwipe. 
 
